Loading stock data…
VIVS
$1.44+0.01 (+0.70%)
Market ClosedLast close May 1
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
VivoSim Labs, Inc. in the Healthcare sector is trading at $1.44. The stock is currently near its 52-week low of $1.25, remaining 34.2% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why VIVS maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.44
Potential Upside
1383.4%
Whystock Fair Value$21.36
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.28M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.84
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.44
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.63%
Volume
Today's trading volume
87,838
Recent News
NIO January Deliveries Nearly Double Year On Year
EV maker opens 2026 with strong momentum
Top Midday Gainers
VivoSim Labs (VIVS) said late Thursday it signed agreements appointing JCBio as its distributor in S
BC-Most Active Stocks
GCL Global Holdings Ltd. 49,480,730 1.29
Wall Street Set to Open Lower Friday as Investors React to Trump's Choice of Warsh as Fed Chair
US stocks look set to open lower in Friday's trading session as investors seem calmed by President D
Rivian vs. NIO: Which EV Manufacturer Stock Is Worth Buying?
RIVN's upcoming R2 SUV, aggressive cost cuts and a multibillion-dollar Volkswagen partnership give it an edge over NIO in the EV stock debate.